Full list of publications at Pubmed: https://tinyurl.com/2ecbb2cm
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk DL, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields A, Cheung NK, Lum LG. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744
Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, Souweidane MM, Greenfield JP, Tickoo S, Lewis JS, Lyashchenko SK, Carrasquillo JA, Chu B, Horan C, Larson SM, Cheung NV, Modak S. Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4.
Park JA and Cheung NK. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. J Immunother Cancer. 2022 Jan;10(1):e003771. doi: 10.1136/jitc-2021-003771.
Hoseini SS, Vadlamudi M, Espinosa-Cotton M, Tran H, Feng Y, Guo HF, Xu H, Cheung I, Cheung NK. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021, May;9(5):e002509. doi: 10.1136/jitc-2021-002509.
Xu H, Buhtoiarov IN, Guo HF, Cheung NK. A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy. Oncoimmunology. 2021 Mar; 10(1):1893500. doi: 10.1080/2162402X.2021.1893500.
Modak S, Zanzonico P, Grkovski M, Slotkin E, Carrasquillo J, Lewis J, Cheung IY, Heaton T, LaQuaglia M, Cheung NK, Pandit-Taskar N. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. J Clin Oncol. 2020, 38(36):4283-4291. doi: 10.1200/JCO.20.01974.
Li S, Liu M, Do MH, Chou C, Stamatiades EG, Nixon BG, Shi W, Zhang X, Li P, Capistrano KJ, Xu H, Cheung NK, Li MO. Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells Nature. 2020 Nov; 587(7832):121-125. doi: 10.1038/s41586-020-2850-3
Santich BH, Park JA, Tran H, Guo HF, Huse M, Cheung NK. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med, 2020 Mar, 12(534):eaax1315. doi: 10.1126/scitranslmed.aax1315.
Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, Lee SG, Bell M, Singh M, Jungbluth AA, Zanzonico PB, Piersigilli A, Larson SM, Cheung NK. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics. 2018 Oct 6;8(18):5106-5125. doi: 10.7150/thno.26585. eCollection 2018.
Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NK, Larson SM, Dunkel IJ. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Aug;19(8):1040-1050. doi: 10.1016/S1470-2045(18)30322-X.
Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P,. Hasan AH, Selvakumar A, O’Reilly RJ, Liu C, Cheung NK. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018 Feb;3(4):e97805. doi: 10.1172/jci.insight.97805.
Cheung IY, Kushner BH, Basu EM, Roberts SS, Modak S, Cheung NK. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology 2017 Jul 31;6(11):e1358331. doi: 10.1080/2162402X.2017.1358331.
Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial. JAMA Oncology. 2018 Dec; 4(12):1729-1735. doi: 10.1001/jamaoncol.2018.4005
Xu H, Guo HF, Cheung IY, Cheung NK. Antitumor efficacy of anti-GD2 IgG1 is enhanced by Fc glyco-engineering. Cancer Immunol Res. 2016 Jul; 4(7):631-638. doi: 10.1158/2326-6066.CIR-15-0221
Ahmed M, Cheng M, Zhao Q, Yehuda G, Cheal SM, Guo HF, Larson SM, and Cheung NK. Humanized Affinity-Matured Monoclonal Antibody 8H9 Has Potent Anti-Tumor Activity and Binds to FG Loop of B7-H3. J Biol Chem. 2015 Dec; 290(50):30018-30029. doi: 10.1074/jbc.M115.679852
Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O’Reilly RJ and Cheung NK. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia. 2015 Nov;29(11):2238-2247, doi: 10.1038/leu.2015.125
Larson SM, Carrasquillo JA, Cheung NK, Press O. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015 Jun;15(6):347-360. doi: 10.1038/nrc3925
Xu H, Cheng M, Guo HF, Chen Y, Huse M, Cheung NK. Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. Cancer Immunol Res. 2015 Mar;3(3):266-77. doi: 10.1158/2326-6066.CIR-14-0230-T
Cheung NK and Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature Reviews Cancer. 2013 Jun; 13(6):397-411. doi: 10.1038/nrc3526.
Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton B, Wang J, Chen X, Becksfort J, Wu J,. Billups CA, Ellison D, Mardis ER, Wilson RK, Downing JR, Dyer MA. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012 Mar; 307(10):1062-1071. doi: 10.1001/jama.2012.228.
Santich BH, Park JA, Tran H, Guo HF, Huse M, Cheung NV. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534). [reprint] [text]